Adjunctive Use of Apyrase to Fibrinolytic Therapy

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$226,120.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43HL095169-01A1
Agency Tracking Number:
HL095169
Solicitation Year:
2009
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2009-2
Small Business Information
APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC., 893 NORTH WARSON ROAD, SAINT LOUIS, MO, 63141
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
192266141
Principal Investigator:
RIDONG CHEN
(314) 608-6932
RCHEN@NIDUSCENTER.COM
Business Contact:
RIDONG CHEN
(314) 812-8054
rchen@niduscenter.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for treatment of acute myocardial infarction. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered human apyrases which exhibit both antiplatelet and anti-inflammatory activities. With the Phase I grant support, we will determine whether optimized human apyrases, in combination with tPA, induce rapid and sustained coronary artery recanalization without increasing bleeding risk. PUBLIC HEALTH RELEVANCE: We will utilize a coronary thrombotic model in dogs to validate whether human apyrase more effectively improve coronary patency than clopidogrel without increasing bleeding risk.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government